



**The University of Western Ontario
Biohazards Subcommittee Meeting**

Minutes of September 14th, 2012
10:00 a.m. – 11:30 a.m., SSB 4220

Present: Dr. J. Millar (Chair), Dr. S. Koval, Dr. S. Siu, Dr. I. Welch, R. Noseworthy, J. Stanley, S. Seaton (OH&S Intern)

Regrets: Dr. S. Barr, Dr. G. Dekaban, Dr. T. deLangley,

1. Introductions

None needed.

2. Approval of Minutes – August 10th, 2012

Motioned: Dr. S. Siu Seconded: R. Noseworthy

3. Office Approvals

There were two office approvals.

4. Biological Agents Registry Forms

4.1 Hess, D.

Approved: No issues.

4.2 Ray, M.

Approved: A signature is required for Section 13.

4.3 Di Guglielmo, J.

Approved: In the description, it should say “10% bleach” instead of “5% sodium hypochlorite”. In Table 1.2, the source/supplier of the organism is required. Table 2.2 should not be filled out as the information is already in Table 2.3. For Question 2.4, “Level 2” should be checked. The name “*E. coli*” should be included in Table

4.2. In Section 5.0, the answers for both SV 40 Large T antigen and E1A should say “yes”. The answer for HTLV should say “no”. The researcher should distinguish whether or not he is using the *E. coli* for cloning or gene expression. If the organism is only being used for cloning, then the maximum quantity to be cultured is too high.

4.4 Dikeakos, J. (Level 3)

Approved: The maximum quantity of *E. coli* to be cultured is too high since the researcher is using the organism for cloning and not gene expression. There are numerous spelling mistakes in the description. In Table 1.2, the containment level for the Human Immunodeficiency Pseudovirus should be clarified. The researcher mentioned Lentivirus in his summary but did not include it in Table 1.2. The Murine Leukemia Virus mentioned in Section 5.0 should also be listed in Table 1.2. The form needs to be reviewed by Dr. Barr or Dr. Dekaban.

4.5 Cairns, E.

Approved: No issues.

4.6 Bhattacharya, M. (Modification)

Approved: Level 2 is adequate.

4.7 Ferguson, S.

Approved: In the description, it should say “10% bleach” instead of “1% bleach”. In section 9.4, the concentration of the agent is given instead of the amount.

4.8 Schild-Poulter, C.

Approved: In Table 1.2, the questions regarding pathogenicity for *E. coli* should say “No”. The Murine Stem Cell Virus listed in Table 4.3 should also be listed in Table 1.2

5. Level 3 Access: Dr. J. Dikeakos (J. Stanley)

This application was approved with no issue.

6. Post Exposure Protocol: HIV Pseudovirus (S. Siu)

University Hospital has switched the post exposure drug to Truvada. Although the evidence in support of this switch is not strong, to remain consistent, the University will be switching to Truvada as well. For after-hours exposures, university workers will be treated in University Hospital’s emergency room within two hours of exposure. For incidents during normal work hours, Workplace Health has two doses on hand.

7. Prophylaxis for Potential B-Virus Exposures (S. Siu)

There is no change in the prophylaxis for B-Virus exposure. The University will continue to use Cyclovir.

8. 2013 Meeting Dates (J. Stanley)

Everyone is still available to meet on Friday mornings.

9. Documents for Website Update (J. Stanley)

There were two documents that only had typographical and logo changes and were corrected in-house. These were the “Procedures for Effective Use of Biological Safety Cabinets” and “Standard Operating Procedures for Autoclaving”.

9.1 Human Blood, Tissues and Body Fluids procedure.

In this document, various formatting and wording changes were made. For number 14, workers should not be instructed to squeeze or scrub the wound directly but rather, they are to encourage bleeding by squeezing the area around the wound. Kristine Brown from Workplace Health will be contacted regarding the official name for Health Services as well as the proper name for Western’s Hepatitis B policy. Item 5 is okay as it stands.

9.2 Lentiviral Policy

Changes were made to the formatting and the wording as well as the approval date.

9.3 Biosecurity Plan

Changes were made to the approval committee as well as the approval date. All references to “The University of Western Ontario” were changed to “Western”. As per committee recommendation however, all references to “Western” should be changed to “Western University”.

9.4 Biosafety Requirements for Imaging

Formatting, wording and approval date changes were made.

9.5 Biosecurity Requirements

For number 8, the link needs to be updated.

10. Next meeting date: October 12th? (J. Stanley)

Drs. Millar, Koval, and Siu will be available on the 12th. Ron Noseworthy is also available.

11. Other Business

(J. Millar)

11.1 Biological Agents Registry Form Update

For future Biohazard Forms, in Section 1.1 regarding CFIA permits, it should say "If No, proceed to Table 1.2".

11.2 Post Exposure Plan for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Dr. Welch discussed a project involving MPTP, a chemical which causes Parkinsonism in animal models. Dr. Siu will liaise with the AUS office to get specific information about the project such as dose, etc. and determine the correct plan to have in place.

12. Adjournment

(J. Millar)

The meeting was adjourned at 10:55 am.